Author: admin

Emphysema Market Expected to rise, 2032 | Mereo BioPharma, United Therapeutics, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Mylan, Novartis, expected to drive market

“Emphysema Market Expected to rise 2032, DelveInsight”
The Emphysema market growth is driven by factors like increase in the prevalence of Emphysema, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Emphysema market report also offers comprehensive insights into the Emphysema market size, share, Emphysema epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Emphysema market size growth forward.

Some of the key highlights from the Emphysema Market Insights Report:

  • In early 2024, the FDA expanded the use of Dupixent, developed by Regeneron Pharmaceuticals and Sanofi, to include chronic obstructive pulmonary disease (COPD), which encompasses emphysema. This marks the first targeted biological therapy approved for COPD. Clinical trials demonstrated that Dupixent reduced moderate-to-severe exacerbations by 30% over 52 weeks and improved lung function, with a favorable safety profile. ​

  • In June 2024, Verona Pharma’s Ohtuvayre received FDA approval as the first inhaled therapy with a novel mechanism of action for COPD in over two decades. Ohtuvayre is a dual inhibitor of the phosphodiesterase 3 and 4 enzymes, offering both bronchodilation and anti-inflammatory effects. Phase 3 trials showed significant improvements in lung function and a 40% reduction in exacerbations over 24 weeks in patients with moderate to severe COPD. ​

  • Olympus Corporation expanded the availability of its Spiration Valve System in March 2022. This minimally invasive device reduces lung hyperinflation in emphysema patients, leading to improved breathing and quality of life. ​

  • According to DelveInsight, the Emphysema Market is projected to grow at a strong rate from 2023 to 2032, driven by the introduction of new therapies and an increasing number of cases.

  • Several leading pharmaceutical and biotechnology companies, including Mereo BioPharma, United Therapeutics, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Pfizer, Mylan, and Novartis, are actively engaged in advancing treatments for emphysema.

  • As per DelveInsight analysis, the Emphysema market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Emphysema Market Landscape

Emphysema Overview

Emphysema is a chronic lung disease that falls under chronic obstructive pulmonary disease (COPD). It causes damage to the air sacs (alveoli) in the lungs, making it difficult to breathe. Over time, the walls of the alveoli weaken and rupture, reducing the surface area available for oxygen exchange. This leads to shortness of breath, coughing, and wheezing.

Do you know the treatment paradigms for different countries? Download our Emphysema Market Sample Report

Emphysema Epidemiology Insights

  • Emphysema is a chronic lung condition characterized by the destruction of alveoli, leading to impaired gas exchange. It is a major component of chronic obstructive pulmonary disease (COPD) and is primarily associated with smoking and environmental pollutants. Here’s an overview of its epidemiology:

  • The Global Burden of Disease (GBD) Study estimates that COPD affects approximately 10–12% of the world’s population over 40 years of age.

Emphysema Epidemiology Segmentation

DelveInsight’s Emphysema market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Emphysema historical patient pools and forecasted Emphysema patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Emphysema Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

  • Emphysema Prevalence

  • Age-Specific Emphysema Prevalence

  • Gender-Specific Emphysema Prevalence

  • Diagnosed and Treatable Cases of Emphysema

Visit for more @ Emphysema Epidemiological Insights

Emphysema Market Outlook

​The emphysema market is poised for significant growth from 2023 to 2032, driven by the rising prevalence of the disease and the introduction of innovative therapies.​

Key Emphysema Market Drivers

  • Increasing Prevalence: Factors such as aging populations and rising smoking rates contribute to a higher incidence of emphysema.​

  • Therapeutic Advancements: Ongoing research and development efforts are leading to the introduction of novel treatments, including regenerative therapies and advanced inhalation devices.​

  • Awareness and Diagnosis: Improved awareness and diagnostic techniques are facilitating earlier detection and intervention.

Emphysema Key Companies

  • Mereo BioPharma, United Therapeutics, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Mylan, Novartis, and others

For more information, visit Emphysema Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Emphysema Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Emphysema, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Emphysema epidemiology in the 7MM

  • Emphysema marketed and emerging therapies

  • Emphysema companies

  • Emphysema market drivers and barriers

Table of Contents:

1 Emphysema Market Key Comprehensive Insights

2 Emphysema Market Report Introduction

3 Competitive Intelligence Analysis for Emphysema

4 Emphysema Market Analysis Overview at a Glance

5 Executive Summary of Emphysema

6 Emphysema Epidemiology and Market Methodology

7 Emphysema Epidemiology and Patient Population

8 Emphysema Patient Journey

9 Emphysema Treatment Algorithm, Emphysema Current Treatment, and Medical Practices

10 Key Endpoints in Emphysema Clinical Trials

11 Emphysema Marketed Therapies

12 Emphysema Emerging Therapies

13 Emphysema: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Emphysema

16 Emphysema Market Key Opinion Leaders Reviews

18 Emphysema Market Drivers

19 Emphysema Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Emphysema Epidemiology 2032

DelveInsight’s “Emphysema – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Emphysema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Emphysema Pipeline 2024

“Emphysema Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Emphysema market. A detailed picture of the Emphysema pipeline landscape is provided, which includes the disease overview and Emphysema treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Emphysema Market Expected to rise, 2032 | Mereo BioPharma, United Therapeutics, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Mylan, Novartis, expected to drive market

Severe Asthma Market Expected to rise, 2034 | AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Boehringer Ingelheim

“Severe Asthma Market Expected to rise 2034, DelveInsight”
The Severe Asthma market growth is driven by factors like increase in the prevalence of Severe Asthma, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Severe Asthma market report also offers comprehensive insights into the Severe Asthma market size, share, Severe Asthma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Severe Asthma market size growth forward.

Some of the key highlights from the Severe Asthma Market Insights Report:

  • In September 2024, Kinaset Therapeutics announced two oral presentations and a late-breaking poster presentation at the 2024 European Respiratory Society (ERS) Congress. These presentations highlight the potential of frevecitinib (KN-002), the company’s lead clinical candidate, for treating moderate to severe asthma and COPD patients.

  • In May 2024, GSK reported positive topline results from its SWIFT-1 and SWIFT-2 Phase III trials, which evaluated the efficacy and safety of depemokimab compared to a placebo in adults and adolescents with severe asthma associated with type 2 inflammation and elevated blood eosinophil counts.

  • In April 2024, Sanofi announced that 25 abstracts covering both approved and investigational treatments would be presented at the American Thoracic Society (ATS) International Conference. A key highlight includes the first Phase IIb data presentation on rilzabrutinib for moderate to severe asthma.

  • Several key pharmaceutical companies, including AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, and others, are developing novel products to improve the Severe Asthma treatment outlook.

  • Severe asthma therapies are Cinqair (reslizumab), Fasenra (benralizumab), GSK3511294 (Depemokimab), PT010, and others.

  • The expansion of the severe asthma market is anticipated to be primarily driven by the increasing prevalence of the condition, advancements in diagnostic techniques, a surge in product launches, and growing pharmaceutical research efforts.

  • Asthma cases diagnosed by severity are categorized into two main groups: Intermittent and Persistent, with the latter further classified into mild, moderate, and severe forms. In 2023, intermittent asthma represented the highest number of cases, totaling approximately 25 million across the 7MM (Seven Major Markets).

  • Within the 7MM, the United States recorded the highest number of severe asthma cases, reaching around 2 million in 2023, followed by Japan with approximately 0.8 million cases.

  • Among the currently approved biologics for severe asthma treatment, Dupixent (dupilumab) is projected to achieve the largest market share by 2034 in the 7MM.

  • With the anticipated approval of new therapies between 2024 and 2034, the severe asthma treatment market is expected to witness significant growth, with a robust compound annual growth rate (CAGR) over the forecast period.

  • As per DelveInsight analysis, the Severe Asthma market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Severe Asthma Market Landscape

Severe Asthma Overview

Severe asthma is a significant challenge among respiratory diseases, marked by persistent and debilitating symptoms that persist despite standard treatments. Unlike milder forms, it often involves ongoing symptoms that greatly impact daily life and overall well-being. This complexity arises from multiple factors, including airway inflammation, structural changes (remodeling), and heightened responsiveness, leading to recurrent bronchial obstruction and airflow restriction. Additionally, the classification of severe asthma into type-2 and non-type-2 inflammation highlights its diverse nature, requiring personalized treatment strategies. While advancements in asthma management have been made, many individuals with severe asthma still struggle to achieve adequate control, emphasizing the critical need for targeted therapies to address this unmet medical challenge.

Do you know the treatment paradigms for different countries? Download our Severe Asthma Market Sample Report

Severe Asthma Epidemiology Insights

  • In 2023, approximately 26 million diagnosed cases of asthma were reported in the United States, encompassing both pediatric and adult populations.

  • Across the 7MM, the total number of diagnosed severe asthma cases reached 5.1 million, accounting for about 9% of all diagnosed asthma cases. Forecasts suggest a significant rise in these numbers by 2034.

Severe Asthma Epidemiology Segmentation

DelveInsight’s Severe Asthma market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Severe Asthma historical patient pools and forecasted Severe Asthma patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Severe Asthma Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

  • Severe Asthma Prevalence

  • Age-Specific Severe Asthma Prevalence

  • Gender-Specific Severe Asthma Prevalence

  • Diagnosed and Treatable Cases of Severe Asthma

Visit for more @ Severe Asthma Epidemiological Insights

Severe Asthma Treatment Market

Severe asthma is characterized not only by difficult-to-control symptoms but also by significant abnormalities in pulmonary function. Accurate diagnosis is challenging due to the lack of precise physiological characterization, often relying on symptom assessment and treatment response.

Diagnosis typically involves confirming episodic airflow obstruction or airway hyperresponsiveness and assessing reversibility through spirometry. A key indicator is an increase in FEV1 (forced expiratory volume in one second) by >200 mL and 12% after inhaling a short-acting beta-agonist (SABA).

Treatment primarily focuses on reducing airway inflammation and preventing symptoms. Inhaled corticosteroids (ICS) are the cornerstone for persistent asthma, while SABAs provide quick relief during acute symptoms. If asthma remains uncontrolled, additional long-term controller medications such as long-acting beta-agonists (LABAs), montelukast, or theophylline may be introduced. Oral corticosteroids are considered for patients with persistent symptoms and flare-ups.

For severe cases, six approved monoclonal antibodies (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab) serve as biologic add-on therapies. However, no approved treatments currently exist for severe non-eosinophilic asthma, which does not respond to corticosteroids.

Severe Asthma Market Outlook

The Severe Asthma market is evolving with a focus on reducing symptoms, minimizing side effects, and maintaining normal activity levels. Management strategies prioritize disease severity and the selection of appropriate therapies to control symptoms and prevent exacerbations.

For mild persistent asthma, low-dose inhaled corticosteroids (ICS) effectively reduce severe attacks and improve control. If symptoms persist, combining ICS with long-acting beta-agonists (LABA) is the preferred approach, along with short-acting beta-agonists (SABA) as needed. An alternative strategy involves using ICS/LABA as both maintenance and reliever therapy.

In severe cases, higher doses of inhalers and additional medications like anticholinergics help relax airway muscles. However, long-term reliance on combination inhaled therapies may be insufficient, and oral steroids pose risks due to potential side effects.

The market is experiencing growth with the development of novel therapies. Leading pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, Bond Avillion, Novartis, Roche, AB Science, and Theravance Biopharma, are actively investing in research and innovation to address unmet medical needs and enhance treatment outcomes for severe asthma patients.

Severe Asthma Marketed Therapies

  • Cinqair (reslizumab): Teva Pharmaceutical

  • Fasenra (benralizumab): AstraZeneca

Severe Asthma Emerging Therapies

  • GSK3511294 (Depemokimab): GlaxoSmithKline

  • PT010: AstraZeneca

Severe Asthma Key Companies

  • AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, and others

For more information, visit Severe Asthma Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Severe Asthma Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Severe Asthma, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Severe Asthma epidemiology in the 7MM

  • Severe Asthma marketed and emerging therapies

  • Severe Asthma companies

  • Severe Asthma market drivers and barriers

Table of Contents:

1 Severe Asthma Market Key Comprehensive Insights

2 Severe Asthma Market Report Introduction

3 Competitive Intelligence Analysis for Severe Asthma

4 Severe Asthma Market Analysis Overview at a Glance

5 Executive Summary of Severe Asthma

6 Severe Asthma Epidemiology and Market Methodology

7 Severe Asthma Epidemiology and Patient Population

8 Severe Asthma Patient Journey

9 Severe Asthma Treatment Algorithm, Severe Asthma Current Treatment, and Medical Practices

10 Key Endpoints in Severe Asthma Clinical Trials

11 Severe Asthma Marketed Therapies

12 Severe Asthma Emerging Therapies

13 Severe Asthma: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Severe Asthma

16 Severe Asthma Market Key Opinion Leaders Reviews

18 Severe Asthma Market Drivers

19 Severe Asthma Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Severe Asthma Epidemiology 2034

DelveInsight’s “Severe Asthma – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Severe Asthma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Severe Asthma Pipeline 2024

“Severe Asthma Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Severe Asthma market. A detailed picture of the Severe Asthma pipeline landscape is provided, which includes the disease overview and Severe Asthma treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Severe Asthma Market Expected to rise, 2034 | AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Boehringer Ingelheim

Pleural Diseases Market Expected to rise, 2032 | Chiesi Farmaceutici, Faron Pharmaceuticals, Actelion Pharmaceuticals, Meril Life Sciences

“Pleural Diseases Market Expected to rise, DelveInsight”
The Pleural Diseases market growth is driven by factors like increase in the prevalence of Pleural Diseases, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Pleural Diseases market report also offers comprehensive insights into the Pleural Diseases market size, share, Pleural Diseases epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Pleural Diseases market size growth forward.

Some of the key highlights from the Pleural Diseases Market Insights Report:

  • Nivolumab and Ipilimumab Combination: In October 2020, the FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the first-line treatment of adults with unresectable MPM. This approval was based on a clinical trial demonstrating a median overall survival of 18.1 months for patients receiving the combination therapy, compared to 14.1 months for those undergoing standard chemotherapy. ​

  • Pembrolizumab (Keytruda): In September 2024, the FDA approved pembrolizumab in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for unresectable advanced or metastatic MPM. This decision was supported by Phase 3 trial data indicating a 21% reduction in the risk of death compared to chemotherapy alone. ​

  • ACES™ Automatic Continuous Effusion Shunt System: In October 2023, the FDA granted 510(k) clearance for the ACES™ System, an innovative, fully implantable device designed to manage chronic pleural effusion without external catheters or frequent hospital visits. Clinical studies are underway to assess its efficacy and impact on patient quality of life.

  • Several key pharmaceutical companies, including Chiesi Farmaceutici, Faron Pharmaceuticals, Actelion Pharmaceuticals, Meril Life Sciences, and others, are developing novel products to improve the Pleural Diseases treatment outlook.

  • As per DelveInsight analysis, the Pleural Diseases market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Pleural Diseases Market Landscape

Pleural Diseases Overview

Pleural diseases affect the pleura, which is the thin, double-layered membrane surrounding the lungs and lining the chest cavity. These diseases can cause inflammation, fluid buildup, or structural issues that affect lung function and cause symptoms like chest pain and difficulty breathing.

Do you know the treatment paradigms for different countries? Download our Pleural Diseases Market Sample Report

Pleural Diseases Epidemiology Segmentation

DelveInsight’s Pleural Diseases market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Pleural Diseases historical patient pools and forecasted Pleural Diseases patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Pleural Diseases Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

  • Pleural Diseases Prevalence

  • Age-Specific Pleural Diseases Prevalence

  • Gender-Specific Pleural Diseases Prevalence

  • Diagnosed and Treatable Cases of Pleural Diseases

Visit for more @ Pleural Diseases Epidemiological Insights

Pleural Diseases Market Outlook

​The global pleural diseases market is experiencing significant growth, driven by advancements in medical technology, increasing prevalence of respiratory disorders, and a focus on personalized medicine.

The pleural diseases market is poised for substantial growth, driven by technological advancements, increasing disease prevalence, and rising investments in healthcare infrastructure. The development of personalized medicine, targeted therapies, and minimally invasive procedures is expected to enhance patient outcomes and quality of life. ​

Pleural Diseases Key Companies

  • Chiesi Farmaceutici, Faron Pharmaceuticals, Actelion Pharmaceuticals, Meril Life Sciences, and others

For more information, visit Pleural Diseases Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Pleural Diseases Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Pleural Diseases, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Pleural Diseases epidemiology in the 7MM

  • Pleural Diseases marketed and emerging therapies

  • Pleural Diseases companies

  • Pleural Diseases market drivers and barriers

Table of Contents:

1 Pleural Diseases Market Key Comprehensive Insights

2 Pleural Diseases Market Report Introduction

3 Competitive Intelligence Analysis for Pleural Diseases

4 Pleural Diseases Market Analysis Overview at a Glance

5 Executive Summary of Pleural Diseases

6 Pleural Diseases Epidemiology and Market Methodology

7 Pleural Diseases Epidemiology and Patient Population

8 Pleural Diseases Patient Journey

9 Pleural Diseases Treatment Algorithm, Pleural Diseases Current Treatment, and Medical Practices

10 Key Endpoints in Pleural Diseases Clinical Trials

11 Pleural Diseases Marketed Therapies

12 Pleural Diseases Emerging Therapies

13 Pleural Diseases: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Pleural Diseases

16 Pleural Diseases Market Key Opinion Leaders Reviews

18 Pleural Diseases Market Drivers

19 Pleural Diseases Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Pleural Diseases Epidemiology 2032

DelveInsight’s “Pleural Diseases – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Pleural Diseases epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Pleural Diseases Pipeline 2024

“Pleural Diseases Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Pleural Diseases market. A detailed picture of the Pleural Diseases pipeline landscape is provided, which includes the disease overview and Pleural Diseases treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pleural Diseases Market Expected to rise, 2032 | Chiesi Farmaceutici, Faron Pharmaceuticals, Actelion Pharmaceuticals, Meril Life Sciences

Digitrix Media Unveils Immersia: A Revolutionary 3D Art Ecosystem for Galleries and Museums

Digitrix Media Unveils Immersia: A Revolutionary 3D Art Ecosystem for Galleries and Museums

Immersia leverages cutting-edge technology to convert a simple 2D image into a three-dimensional masterpiece
Media empowers galleries to thrive in the evolving digital landscape. Digitrix Media launches Immersia, a revolutionary Web2-to-Web3 art platform dubbed “The Artverse.” It transforms 2D artwork into immersive 3D digital twins with brushstrokes and lighting effects. Offering 3,000 customizable 3D galleries, VR access via Meta, and analytics, Immersia bridges physical and digital art. Beta-tested with 200 global artists, it redefines engagement for galleries and museums.

Hong Kong – Digitrix Media, a trailblazer in digital innovation, today announced the launch of Immersia, a groundbreaking Web2-to-Web3 native art platform designed to redefine how art is experienced, shared, and curated. Dubbed “The Artverse,” this ecosystem transforms traditional 2D artwork into immersive 3D digital twins, offering unparalleled opportunities for public and private galleries, museums, artists, and collectors worldwide.

Immersia leverages cutting-edge technology to convert a simple 2D image into a three-dimensional masterpiece. Using proprietary algorithms, the platform recreates visible brushstrokes, lighting effects, and perspective shifts, replicating the in-person viewing experience. This innovation marks a significant leap forward in bridging the physical and digital art worlds.

The platform offers a robust suite of tools tailored to the needs of the modern art ecosystem:

3D Galleries: With an initial capacity of 3,000 virtual galleries, users can craft customizable exhibition spaces in minutes. Supporting paintings, photographs, videos, and more, these galleries are accessible on mobile devices, web browsers, or in virtual reality through partnerships with Meta. Immersive Features: Art enthusiasts can zoom, tilt, and pan artworks in 3D, while galleries can host live events, video-enhanced exhibitions, and podcasts to deepen engagement. Analytics and Insights: Artists and curators gain access to detailed dashboards, enabling them to track performance, analyze audience preferences, and refine their strategies.

Designed with accessibility in mind, Immersia’s intuitive interface removes the technical hurdles often linked to Web3 adoption, making it approachable for creators of all skill levels. During its beta phase, Digitrix Media partnered with 200 international artists, collectors, and universities, incorporating real-world feedback to perfect the platform’s features.

Immersia is poised to transform how galleries and museums—both public and private—engage with their audiences. From virtual exhibitions to data-driven insights, the platform offers a scalable solution for institutions seeking to modernize their offerings while preserving the essence of art.

About Digitrix Media

Digitrix Media is a forward-thinking technology company dedicated to pushing the boundaries of digital experiences. With a focus on innovative solutions, Digitrix Media empowers galleries to thrive in the evolving digital landscape.

Media Contact
Company Name: Digitrix Media
Contact Person: Jasper Kit
Email: Send Email
Country: HongKong
Website: https://www.digitrixtech.com/

Historic Hong Kong Exhibition Showcases Filipino Artistic Talent Across Borders

Historic Hong Kong Exhibition Showcases Filipino Artistic Talent Across Borders

Poster of “Unity in Diversity: Filipino Artists Across Borders,” exhibition at the Hong Kong Visual Arts Centre
A vibrant celebration of Filipino creativity unfolds in Hong Kong with the exhibition “Unity in Diversity: Filipino Artists Across Borders,” showcasing over 70 master works from artists in Hong Kong, the Philippines, New York, and the UK. Running from February 26 to March 3, 2025, it highlights diverse artistic expressions, inviting reflection on identity and cultural heritage. Curated by Hong Kong-based artists Rodolfo Canete Jr. and Abigail Camaya-Hills

HONG KONG – A vibrant celebration of Filipino creativity is captivating audiences in Hong Kong, where the community of Filipinos in the city is finding inspiration in the works of their compatriots. An art exhibition titled “Unity in Diversity: Filipino Artists Across Borders” opened this week, featuring more than 70 masterpieces crafted by Filipino artists from Hong Kong, the Philippines, New York, and the United Kingdom. This is probably the single biggest overseas exhibition of contemporary Filipino artists ever.

The exhibition, held at the Hong Kong Visual Arts Center from February 26 to March 3, showcases an array of artistic expressions, including intricate sculptures, vivid paintings, woven textiles, and other stunning creations. Consul General of the Philippines in Hong Kong, Germinia Aguilar-Usudan, hailed the event as a testament to the ingenuity and spirit of Filipino artists, whose works are resonating not only with the Filipino diaspora but also with a broader international audience.

Among the exhibition’s standout participants is Ferdinand Cacnio, the guest of honor, whose presence elevates the opening festivities. Renowned for his mastery in sculpting, Cacnio unveils a stunning collection of brass sculptures that meld fluidity with precision. For the first time in Hong Kong, he also presents his paintings, offering a rare glimpse into the versatility of this celebrated artist. His works serve as a bridge between tradition and innovation, setting the tone for an exhibition that promises to push artistic boundaries.

Joining Cacnio is Norman Dreo, a painter par excellence whose meticulous attention to detail pays homage to the Old Masters. Dreo’s two paintings are a labor of love, each stroke echoing the timeless techniques of classical artistry while infusing them with a contemporary Filipino spirit. His works invite viewers to linger, uncovering layers of meaning in their intricate compositions.

The exhibition also celebrates the evocative power of abstract expression through Lydia Velasco’s striking Filipino female figures. Velasco’s bold forms capture the essence of womanhood, blending strength and grace in a dance of shapes and shadows. Equally compelling is Richard Dela Cruz’s storytelling, where Rococo-inspired engravings come alive with narrative depth, drawing viewers into a world of ornate elegance and hidden tales.

Innovation takes center stage with Boholana artist Nicole Asares, whose outline-embossed paintings defy conventional boundaries. Her creations leap across the canvas, intertwining form and imagination in a mesmerizing dance that challenges the viewer’s perception. Similarly, Jeff Dahilan’s meticulous triangular mosaics offer a geometric symphony of color and texture, each piece a testament to patience and precision. Meanwhile, “rockstar” painter Kenneth John Montegrande enchants with his sublime blue-toned landscape, where serene hues evoke a meditative stillness that resonates deeply.

A significant highlight of this exhibition is the debut of Kareem Moumina, a prolific Filipino-Arab-American artist based in New York. Marking his first appearance in a Filipino art exhibition, Moumina’s huge oil painting commands attention with its fusion of tropical settings and dreamlike elements influenced by visits to the native land of his Filipino mother. His work explores the beauty of diversity—an interplay of cultures and visions that mirrors the exhibition’s overarching theme. Through his bold brushstrokes and vibrant palette, Moumina invites viewers to reflect on the interconnectedness of identity and environment, making his contribution a fitting crescendo to this artistic celebration.

This landmark exhibition not only showcases the brilliance of individual artists but also underscores the collective strength of Filipino creativity on the global stage. From Cacnio’s sculptural innovations to Moumina’s cross-cultural narratives, each contributor weaves a thread into a larger story—one of heritage, imagination, and resilience. For a full list of participating artists, click here, and prepare to be inspired by a display that transcends borders and redefines artistic possibility.

“These works are more than just art; they’re a bridge connecting Filipinos across the world and showcasing our talent to others,” Aguilar-Usudan said during the opening ceremony. Visitors from various backgrounds have expressed awe at the skill and creativity on display, with many noting the universal appeal of the pieces.

The event underscores Hong Kong’s role as a cultural hub for the Filipino community, which forms one of the city’s largest expatriate groups. For the artists, it’s an opportunity to share their heritage and stories through a kaleidoscope of mediums, proving that creativity knows no borders.

The exhibition is jointly curated by Hong Kong-based artists Rodolfo Canete Jr. and Abigail Camaya Hills of Galleria Camaya.

As the exhibition continues through the week, it promises to leave a lasting impression on all who witness the remarkable talent of Filipino artists thriving across the globe.

Media Contact
Company Name: Galleria Camaya
Contact Person: Gail Hills
Email: Send Email
Country: HongKong
Website: https://galleriacamaya.art

“Pennygirl’s Rescue” Receives Esteemed Literary Titan Gold Book Award for Its Heartwarming Tale of Courage and Second Chances

“Pennygirl’s Rescue,” the bestselling and award-winning children’s book by Judy McGee, has been honored with the Literary Titan Gold Book Award for its inspiring story of a brave rescue dog seeking love and belonging.

Judy McGee’s beloved children’s book, Pennygirl’s Rescue, has received the esteemed Literary Titan Gold Book Award, celebrating its compelling narrative and powerful message of love, resilience, and second chances. This honor marks the second award for the book, further solidifying its place as a must-read for animal lovers and young readers alike.

Pennygirl’s Rescue follows the touching journey of Penny, a lovable Lab mix who unexpectedly finds herself in a city shelter, far from the Texas farm she once called home. As Penny navigates her new reality, she encounters kindness, friendship, and the unwavering hope of finding a forever family. Through engaging storytelling, Judy McGee brings Penny’s experiences to life, showcasing the importance of dog rescue and adoption. The book’s inspiring themes resonate deeply with readers, reinforcing the idea that love and second chances can come in the most unexpected ways.

A glowing review from Literary Titan praises McGee’s writing as “charming and evocative, full of warmth and gentle humor,” capturing Penny’s innocence and resilience with touching sincerity. The review highlights Penny’s journey as one filled with courage, patience, and joy—qualities that make her story a heartwarming read for children and adults alike.

This award is a testament to McGee’s ability to craft a story that not only entertains but also raises awareness about animal rescue efforts. With Pennygirl’s Rescue being the first installment of The Pennygirl Series, readers can look forward to more adventures featuring the lovable rescue dog.

Experience the heartwarming journey of Penny and discover why this award-winning book is capturing the hearts of readers everywhere! Perfect for children, animal lovers, and anyone who believes in second chances, Pennygirl’s Rescue is a must-read.

Order now on Amazon or Barnes & Noble and bring home this inspiring story of love, courage, and friendship.

About the Author

Judy McGee is an award-winning author based in Trenton, Ontario, Canada. Originally from Mississauga, Judy spent her career as a Registered Ultrasound Technologist before embracing her passion for storytelling. A dedicated wife, mother, and grandmother, she finds joy in crafting heartfelt narratives inspired by her own rescue dog, Penny. When she’s not writing, Judy enjoys sewing, crafting, and gardening. Pennygirl’s Rescue is her debut children’s book, now a two-time award winner, having received both The Literary Titan Gold Book Award and The Golden Wizard Book Prize.

Dive deeper into the heartwarming world of Pennygirl’s Rescue and explore more about award-winning author Judy McGee! Visit her official website to learn about her books and upcoming releases, read her blog for behind-the-scenes insights and heartfelt stories, and stay updated on Penny’s adventures and animal rescue advocacy. 

Visit: www.judymcgeeauthor.com

Media Contact
Company Name: Literary Titan
Contact Person: Judy McGee
Email: Send Email
Country: United States
Website: https://www.judymcgeeauthor.com/

SMRTR Solutions to Exhibit at SQF Unites 2025, Bringing the Future of Business Process Automation

SMRTR Solutions will show how intelligent automation and AI technologies are within reach of any business. The industry leader in sustainable business process automation solutions will also demonstrate how these tools can be used for food safety collaboration and education.

SMRTR Solutions is excited to announce its participation in SQF Unites 2025 as an exhibitor. The industry leader in sustainable business automation solutions and digital transformation tools will showcase its extensive suite of intelligent automation and AI technologies for the food industry at the “Coming Together for Food Safety” event in Orlando from March 2nd to 5th.

SQF Unites 2025 provides a unique opportunity for food safety professionals, compliance experts, and industry leaders to learn how technological advancements are pushing boundaries to improve food safety, quality assurance, and regulatory compliance. According to Susanne Moore, CEO of SMRTR, the fast-approaching FSMA 204 deadlines have made traceability and compliance critical considerations for businesses in the food industry. This event, centered around compliance and automation, comes at a time when businesses need to revolutionize how they operate, and SMRTR is thrilled to be at the forefront of this transformation.

With over 21 years of experience, SMRTR Solutions has demonstrated its ability to help businesses across industries automate their business processes. The company develops AI-driven applications that optimize operations, provide traceability, and ensure regulatory compliance for the Food and Beverage industry. Its intelligent automation solutions also help businesses modernize their accounting processes, streamline operations, and achieve their growth goals. From reducing paper usage through its Enterprise Content Management solution to mitigating risk with its Regulatory Compliance Portal, SMRTR Solutions turns complex workflows into seamless, automated processes, simplifies compliance with industry standards, boosts efficiency, and slashes costs.

“Manual processes just don’t cut it anymore,” said Susanne. “Businesses need to work smarter not harder, and that is what our tools are designed to do. We make food safety and supply chain management seamless, stress-free and fast, to help businesses improve traceability, reduce errors, and stay ahead of compliance regulations.”

At booth 36, food safety professionals, industry leaders, and compliance experts will speak with SMRTR Solutions about smarter ways to connect people to information and processes. The company will demonstrate how it helps businesses work smarter, not harder, with process automation tools that streamline operations, ensure compliance, and boost efficiency.

“We are beyond excited to exhibit at SQF Unites 2025,” added Susanne. “This event is the perfect stage for us to showcase how our business process automation tools can transform the way businesses in the food industry operate. We look forward to demonstrating in person how our tools streamline food safety processes, optimize supply chains and more.”

Ahead of the March 2-5 event, SMRTR Solutions invites businesses and professionals to visit its LinkedIn page for event highlights and to learn more about automation and how it can help businesses achieve operational efficiency and compliance.

See event details for more information about SMRTR Solutions’ participation in SQF Unites 2025, or visit the company website to learn more about its business automation tools, which are helping businesses stay ahead of evolving regulations.

Media Contact
Company Name: SMRTR Solutions
Contact Person: Susanne
Email: Send Email
Country: United States
Website: https://smrtrsolution.com/

Brinkerhoff Property Management & Real Estate Expands Services to Enhance Property Management in Denver

The company extends its dedication to property owners and renters by spreading its full-fledged property management and real estate services throughout the Denver Metro area.

Brinkerhoff Property Management & Real Estate has spread out its operations for better property management services throughout the Denver Metro area.

With a focus on optimizing property value and facilitating smooth operations, the company remains the first choice for expert rental property management services.

As one of the top property management firms in the area, Brinkerhoff Property Management & Real Estate offers a complete range of property management services, including rent collection, tenant screening, lease enforcement, and maintenance of the property. The firm is an expert in Denver property management, providing tailored solutions that cater to the specific needs of property owners and investors.

In addition to its full-service rental property management, the company offers lease-only services for landlords who prefer to manage their properties independently but require assistance in securing tenants.

With strong roots in Golden Property Management and Arvada Property Management, Brinkerhoff Property Management & Real Estate remains committed to serving property owners with localized knowledge.

The in-depth knowledge of the Denver rental market by the company enables it to deliver customized solutions that optimize occupancy levels to guarantee long-term tenant satisfaction.

“Our growth is a testament to our ongoing dedication to providing excellent property management services in the Denver Metro region,” stated Pamela, Brinkerhoff Property Management & Real Estate’s spokesperson. “We provide full-service rental property management services as our goal is to equip property owners with the knowledge and assistance necessary to manage their investments effectively.”

Awarded for industry knowledge and customer-focused service, Brinkerhoff Property Management & Real Estate establishes itself as a reliable expert in property management. The firm’s dedication to clarity, effectiveness, and superior quality of service won the trust of both property owners and renters.

One of the clients, David Mitchell of Denver explained his experience with the company, “Brinkerhoff Property Management & Real Estate has been excellent for my rental properties in Denver. Their professionalism, timely communication, and attention to detail have provided me peace of mind, knowing that my investments are in good hands.”

Another client, Sarah from Avada, said, “I have used a number of property management firms, but none have been as responsive and dependable as Brinkerhoff Property Management & Real Estate. Their staff takes care of everything, from tenant screening to maintenance, with efficiency and care.”

With a record of success in providing sound property management services, Brinkerhoff Property Management & Real Estate has become a leader in the industry as it is highly regarded for its commitment to excellence.

About Brinkerhoff Property Management and Real Estate

Brinkerhoff Property Management & Real Estate deals in the leasing and management of single-family and commercial rental homes within the Denver Metro area.

With an emphasis on integrity, accountability, and superior service, the business provides full-service property management and real estate brokerage services, ensuring that clients’ investments are profitable and well-managed.

For more information, refer to the details below.

Media Contact
Company Name: Brinkerhoff Property Management and Real Estate
Contact Person: Pamela
Email: Send Email
Country: United States
Website: https://brinkerhoffpm.com

Wohrman Dental Group: Delivering Exceptional Care and Emergency Dental Services in Memphis

Wohrman Dental Group has been leading the way in Memphis for more than thirty years in delivering complete dental treatments and a special mix of dependable emergency services combined with individualized care. Under the direction of extremely talented dentist Dr. Tyler Wohrman, who enjoys helping individuals improve their oral health, Wohrman Dental Group is a family-owned clinic dedicated to treating patients with the dignity and respect they merit.

The clinic provides oral crisis treatments in addition to general dentistry, restorative dentistry, cosmetic dentistry, sedation dentistry, and emergency dental work. This dental clinic based in Memphis distinguishes itself from the others with its first-rate patient care and dedication to keeping Memphis citizens’ smiles natural and attractive. The Wohrman Dental Group staff is genuine and always ready to address any developing concerns or inquiries.

“At Wohrman Dental Group, we understand that each patient has unique needs, and we are dedicated to offering the best care tailored to those needs,” said Dr. Tyler Wohrman. “We’re proud to serve as Memphis’ go-to emergency dentist, providing immediate care when it matters most, including emergency extractions, root canals, and dental crowns.”

Apart from routine visits and preventative treatments, Wohrman Dental Group is outstanding in emergency dental surgeries. Whether patients need emergency dental extractions or urgent root canal therapy, the clinic ensures quick treatment even outside of regular business hours. By this dedication to availability, Wohrman Dental Group sets itself out among the few dentist offices in Memphis offering 24-hour care for dental emergencies.

The clinic is renowned for its flexible schedule, which includes weekend hours to fit patients’ hectic schedules. Wohrman Dental Group, a reputable emergency dentist, facilitates the urgent care people require regardless of the time of day or week.

The extensive restorative and cosmetic dental training and experience of Dr. Tyler Wohrman guarantees patients get the best possible treatment. He is a master in dental extractions and root canals; his office features the newest dental technologies to provide quick and successful treatment

“We believe in compassionate care, especially in emergencies,” added Dr. Wohrman. “It’s important to us that patients feel comfortable, informed, and confident in the care they receive. We’re here to take care of our community’s dental health and improve their quality of life.”

PVisitors at Wohrman Dental Group should expect a cheerful, family-friendly atmosphere where their smiles come first, and their worries are listened to. From emergency treatments to preventative care, Wohrman Dental Group continues to be a pillar of oral health in Memphis.

Serving the community for more than thirty years, Memphis, Tennessee-based Wohrman Dental Group is a family-owned dental clinic. Under Dr. Tyler Wohrman, the clinic offers general, restorative, cosmetic, and emergency dentistry, among other dental treatments. The clinic aims to satisfy every patient’s dental need with flexibility and convenience and is committed to providing individualized, mild treatment.

Media Contact
Company Name: Wohrman Dental Group
Contact Person: Tyler
Email: Send Email
Country: United States
Website: https://www.wohrmandentalgroup.com/

Celebrating Nearly Two Decades of Success, NEXDINE Hospitality Achieves New Milestone

A rapidly growing dining services and facility management company serving America’s most discerning businesses, independent schools, senior living communities, and hospitals.

Proudly celebrating 17 years of excellence, NEXDINE, a dining, hospitality service, and facilities management company, continues to set the bar. NEXDINE Hospitality is committed to creating life-long experiences for businesses, independent schools, senior living communities, hospitals, and healthcare systems by offering authentic food and service. The company specializes in tailoring its hospitality services to fit the unique needs and desires of each client, thereby offering a personalized experience. This achievement reflects the company’s unwavering dedication to delivering the utmost level of service to its clientele.

Through its dedication to innovation and personalization, NEXDINE Hospitality service has established close relationships with over 100 client locations and has more than 2,000 professionals as part of its staff, providing outstanding experiences for each client and community. “Achieving this milestone in success is a reflection of trust our clients have in us and the unrelenting dedication of our team,” says David Lanci, Co-Founder and CEO of NEXDINE Hospitality. “We are excited to continue building on this legacy for years to come.”

What Makes NEXDINE Hospitality Different from Others?

NEXDINE differentiates itself in the hospitality services management sector by placing a strong emphasis on custom solutions, great dining experiences, and sustainability. The customer-centric philosophy of the company means that each partnership is individually designed to address specific requirements, be it corporate dining, healthcare, senior living, or education. With the focus on fresh, and quality ingredients and innovative dining concepts, memorable experiences are always the result. Furthermore, its dedication to sustainable business practices, together with excellent customer service, solidifies its reputation as a reliable industry leader.

Sustaining Excellence: NEXDINE’s Commitment to Quality, Safety, and Innovation

As the company celebrates nearly two decades of success, its commitment to excellence remains at the top of quality and safety through the adoption of industry best practices, rigorous training regimens, and regular audits to provide exemplary food safety and service. Acclaimed for innovative and sustainable solutions, NEXDINE consistently elevates client dining experiences while placing health and wellness at the forefront of its mission.

“Hospitality begins with the treatment and focus of our colleagues and culture. This philosophy is the cornerstone of all our decision-making and a key contributor to our growth,” says Larry Abrams, President and Managing Partner of NEXDINE Hospitality.

For more information, please visit the company’s website at https://nexdine.com or reach out via the contact details listed.

About NEXDINE Hospitality

Established in 2008, NEXDINE has become the fastest-growing dining service management and hospitality company in the industry. This company was named the ‘Top Riser’ in revenue growth rate for two years running by Food Management and ranked in the nation’s Top 50 Food Service Management Companies. Having a deep understanding of the impact of the dining experience on happiness, productivity, and satisfaction, NEXDINE continues to work to redefine hospitality by delivering customized, high-quality dining solutions.

Media Contact
Company Name: NEXDINE
Contact Person: Crystal
Email: Send Email
Country: United States
Website: https://nexdine.com/